More interestingly, Lee et al., recently discovered that venetoclax directly enhanced the effector function of double-negative T cells, used as surrogate of leukemia-specific T cells, and CD8+ T cells from healthy donors by increasing reactive-oxygen species generation, thereby increasing cytotoxicity against AML cells in vitro and in vivo [80]. This evidence concerns the gene CD8A and leukemia.